Research Article 
Effects of Prescription Omega-3-Acid Ethyl Esters Plus Simvastatin on Lipids and Lipoprotein Particles in Mixed Dyslipidemia
Kevin Carl Maki, Mary R. Dicklin, Barry C. Lubin, James M. McKenney and Matthew S. Reeves
Journal of Clinical Lipidology, 2008, 2(3), 222-223. DOI: 10.1016/j.jacl.2008.04.038
Abstract
not available
ASCI-ID: 2746-50
Similar Articles
Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia
Journal of Clinical Lipidology, 2008, 2(1), 12-18. DOI: 10.1016/j.jacl.2007.12.001
Lipid metabolism in children and adolescents: Impact on vascular biologyJournal of Clinical Lipidology, 2008, 2(3), 127-137. DOI: 10.1016/j.jacl.2008.04.002
Pediatric dyslipidemias: Prescription medication efficacy and safetyJournal of Clinical Lipidology, 2008, 2(3), 189-201. DOI: 10.1016/j.jacl.2008.04.008
Initial Results of a Home Patient Screening Kit for Diabetes and DyslipidemiaJournal of Clinical Lipidology, 2008, 2(3), 202-203. DOI: 10.1016/j.jacl.2008.04.011
ABT-335 in Combination with Rosuvastatin Improves Multiple Lipid Ratios in Patients with Mixed DyslipidemiaJournal of Clinical Lipidology, 2008, 2(3), 211-212. DOI: 10.1016/j.jacl.2008.04.023
Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination with Rosuvastatin in Patients with Mixed Dyslipidemia: A Phase 3 StudyJournal of Clinical Lipidology, 2008, 2(3), 218-219. DOI: 10.1016/j.jacl.2008.04.031
Effects of ABT-335 in Combination with Rosuvastatin on Low-Density Lipoprotein Particle Size in Patients with Mixed DyslipidemiaJournal of Clinical Lipidology, 2008, 2(3), 219-220. DOI: 10.1016/j.jacl.2008.04.032
Clinical and laboratory assessment of cardiovascular risk in children: Guidelines for screening, evaluation, and treatmentJournal of Clinical Lipidology, 2008, 2(4), 248-266. DOI: 10.1016/j.jacl.2008.06.003
A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the “Back of the Line” as a therapy for dyslipidemia?Journal of Clinical Lipidology, 2008, 2(5), 313-317. DOI: 10.1016/j.jacl.2008.06.011
Chronic kidney disease as a cardiovascular risk state and considerations for the use of statinsJournal of Clinical Lipidology, 2008, 2(5), 318-327. DOI: 10.1016/j.jacl.2008.06.008
Optimal management of lipids in diabetes and metabolic syndromeJournal of Clinical Lipidology, 2008, 2(5), 335-342. DOI: 10.1016/j.jacl.2008.08.444
Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular eventsJournal of Clinical Lipidology, 2008, 2(5), 343-353. DOI: 10.1016/j.jacl.2008.06.009
Lipid therapy utilization rates in a managed-care mixed dyslipidemia populationJournal of Clinical Lipidology, 2008, 2(5), 365-374. DOI: 10.1016/j.jacl.2008.08.443
Dyslipidemia in South Asians living in a western communityJournal of Clinical Lipidology, 2009, 3(1), 14-18. DOI: 10.1016/j.jacl.2008.12.002
Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemiaJournal of Clinical Lipidology, 2009, 3(1), 33-38. DOI: 10.1016/j.jacl.2008.12.007
Prevalence of dyslipidemia in normoglycemic subjects with newly diagnosed high blood pressure in Abuja, NigeriaJournal of Clinical Lipidology, 2009, 3(1), 51-56. DOI: 10.1016/j.jacl.2008.12.001
Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?Journal of Clinical Lipidology, 2009, 3(2), 70-77. DOI: 10.1016/j.jacl.2009.02.001
Flushing and other dermatologic adverse events associated with extended-release niacin therapyJournal of Clinical Lipidology, 2009, 3(2), 101-108. DOI: 10.1016/j.jacl.2009.02.003
Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME StudyJournal of Clinical Lipidology, 2009, 3(2), 109-118. DOI: 10.1016/j.jacl.2009.02.009
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studiesJournal of Clinical Lipidology, 2009, 3(2), 125-137. DOI: 10.1016/j.jacl.2009.02.007
Efficacy and tolerability of multidrug therapy for hypertriglyceridemiaJournal of Clinical Lipidology, 2009, 3(5), 341-344. DOI: 10.1016/j.jacl.2009.09.003
Prevalence of dyslipidemia and its associated factors among Jordanian adultsJournal of Clinical Lipidology, 2010, 4(1), 53-58. DOI: 10.1016/j.jacl.2009.12.004
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087Journal of Clinical Lipidology, 2010, 4(4), 279-287. DOI: 10.1016/j.jacl.2010.04.003
Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart diseaseJournal of Clinical Lipidology, 2010, 4(4), 293-297. DOI: 10.1016/j.jacl.2010.06.003
Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutationJournal of Clinical Lipidology, 2010, 4(4), 310-313. DOI: 10.1016/j.jacl.2010.06.004
Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel diseaseJournal of Clinical Lipidology, 2010, 4(6), 478-482. DOI: 10.1016/j.jacl.2010.08.021
Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndromeJournal of Clinical Lipidology, 2010, 4(6), 515-521. DOI: 10.1016/j.jacl.2010.08.020
A survey on blood lipid levels among newborns and healthy inhabitants in urban Shanghai (2008-2009)Journal of Clinical Lipidology, 2011, 5(5), 380-386. DOI: 10.1016/j.jacl.2011.06.015
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L)Journal of Clinical Lipidology, 2011, 5(5), 401-407. DOI: 10.1016/j.jacl.2011.06.010
Antisense therapy and emerging applications for the management of dyslipidemiaJournal of Clinical Lipidology, 2011, 5(6), 441-449. DOI: 10.1016/j.jacl.2011.08.007
A systematic review on evidence of the effectiveness and safety of a wax-matrix niacin formulationJournal of Clinical Lipidology, 2012, 6(2), 121-131. DOI: 10.1016/j.jacl.2011.07.003
Efficacy and Safety of Fenofibric Acid + Rosuvastatin Versus Rosuvastatin Alone in Patients With Mixed Dyslipidemia and Stage 3 Chronic Kidney DiseaseJournal of Clinical Lipidology, 2012, 6(3), 269-270. DOI: 10.1016/j.jacl.2012.04.040
Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006Journal of Clinical Lipidology, 2012, 6(4), 325-330. DOI: 10.1016/j.jacl.2012.05.002
Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate “no-flush” niacin in persons with mild to moderate dyslipidemiaJournal of Clinical Lipidology, 2013, 7(1), 14-23. DOI: 10.1016/j.jacl.2012.10.004
Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterolJournal of Clinical Lipidology, 2013, 7(3), 194-198. DOI: 10.1016/j.jacl.2013.02.003
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) studyJournal of Clinical Lipidology, 2013, 7(3), 199-207. DOI: 10.1016/j.jacl.2013.01.006
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid AssociationJournal of Clinical Lipidology, 2013, 7(4), 304-383. DOI: 10.1016/j.jacl.2013.04.001
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucoseJournal of Clinical Lipidology, 2013, 7(5), 423-432. DOI: 10.1016/j.jacl.2013.06.001
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) studyJournal of Clinical Lipidology, 2013, 7(6), 615-625. DOI: 10.1016/j.jacl.2013.09.002
Dyslipidemia and associated risk factors in a resettlement colony of DelhiJournal of Clinical Lipidology, 2013, 7(6), 653-660. DOI: 10.1016/j.jacl.2013.06.003
Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemiaJournal of Clinical Lipidology, 2013, 7(6), 671-674. DOI: 10.1016/j.jacl.2013.05.003
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full reportJournal of Clinical Lipidology, 2014, 8(1), 29-60. DOI: 10.1016/j.jacl.2013.12.005
Lipid abnormalities in foreign-born and US-born patients in a medical groupJournal of Clinical Lipidology, 2014, 8(1), 77-85. DOI: 10.1016/j.jacl.2013.10.007
Prevalence of dyslipidemia and associated risk factors in Turkish adultsJournal of Clinical Lipidology, 2014, 8(2), 206-216. DOI: 10.1016/j.jacl.2013.12.011
Hypothyroidism as a risk factor for statin intoleranceJournal of Clinical Lipidology, 2014, 8(4), 401-407. DOI: 10.1016/j.jacl.2014.05.005
Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adultsJournal of Clinical Lipidology, 2014, 8(1), 86-93. DOI: 10.1016/j.jacl.2013.11.001
Combined dyslipidemia in obese children: Response to a focused lifestyle approachJournal of Clinical Lipidology, 2014, 8(2), 181-186. DOI: 10.1016/j.jacl.2014.01.003
Non-HDL-cholesterol in an adolescent diabetes populationJournal of Clinical Lipidology, 2014, 8(2), 194-198. DOI: 10.1016/j.jacl.2013.12.006
National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - executive summaryJournal of Clinical Lipidology, 2014, 8(5), 473-488. DOI: 10.1016/j.jacl.2014.07.007
Effects of ABT-335 in Combination with Rosuvastatin on Low-Density Lipoprotein Particle Size in Patients with Mixed DyslipidemiaJournal of Clinical Lipidology, 2008, 2(3), 219-220. DOI: 10.1016/j.jacl.2008.04.032
Cholesterol, lipoproteins, and cognitive impairmentJournal of Clinical Lipidology, 2009, 3(6), 368-371. DOI: 10.1016/j.jacl.2009.10.002
Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidenceJournal of Clinical Lipidology, 2010, 4(1), 69-71. DOI: 10.1016/j.jacl.2009.12.003
Extremely elevated lipoprotein(a), combined hyperlipidemia, and premature atherosclerosis in a Chinese familyJournal of Clinical Lipidology, 2010, 4(6), 543-547. DOI: 10.1016/j.jacl.2010.09.002
Drugs in development for management of lipoprotein disordersJournal of Clinical Lipidology, 2011, 5(2), 66-75. DOI: 10.1016/j.jacl.2011.01.004
Changes in Lipoprotein-associated Phospholipase A2 with Ezetimibe/Simvastatin Co-administered with ER Niacin in Type II HyperlipidemiaJournal of Clinical Lipidology, 2012, 6(3), 253-254. DOI: 10.1016/j.jacl.2012.04.011
Changes in Lipoprotein Particle Number with Ezetimibe/Simvastatin Co-administered with Extended-Release Niacin in Patients with Type II HyperlipidemiaJournal of Clinical Lipidology, 2012, 6(3), 254-255. DOI: 10.1016/j.jacl.2012.04.012
Body fat distribution, lipoprotein metabolism, and insulin resistance: A lifetime of research on the pathophysiology of the human metabolic syndromeJournal of Clinical Lipidology, 2012, 6(6), 601-603. DOI: 10.1016/j.jacl.2012.08.006
Relationships between alcohol intake and atherogenic indices in womenJournal of Clinical Lipidology, 2013, 7(5), 454-462. DOI: 10.1016/j.jacl.2013.03.009
Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: A cost-effectiveness analysisJournal of Clinical Lipidology, 2013, 7(6), 642-652. DOI: 10.1016/j.jacl.2013.06.004
JCL Roundtable: Health information technology in the management of lipoprotein disordersJournal of Clinical Lipidology, 2014, 8(2), 137-147. DOI: 10.1016/j.jacl.2013.12.009